Dinapsolin

Dinapsolin
IUPAC ime
	8,9-dihidroksi-2,3,7,11b-tetrahidro-1H-naf[1,2,3-de]izohinolin
Identifikatori
CAS broj	458563-40-1
ATC kod	none
PubChem	CID 9816455
Hemijski podaci
Formula	C16H15NO2
Molarna masa	253,295 g/mol
	SMILES C4NCC1c3c4cccc3Cc2c1ccc(O)c2O; ;

Dinapsolin je lek koji je razvijen za treatman Parkinsonove bolesti.^[1] On deluje kao selektivni puni agonist dopaminskog D₁ receptora.^[2]^[3]^[4]^[5]

Reference

^ Gulwadi AG, Korpinen CD, Mailman RB, Nichols DE, Sit SY, Taber MT (2001). „Dinapsoline: characterization of a D1 dopamine receptor agonist in a rat model of Parkinson's disease”. The Journal of Pharmacology and Experimental Therapeutics. 296 (2): 338—44. PMID 11160615.
^ Ghosh D, Snyder SE, Watts VJ, Mailman RB, Nichols DE (1996). „9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore”. Journal of Medicinal Chemistry. 39 (2): 549—55. PMID 8558526. doi:10.1021/jm950707.
^ Sit SY, Xie K, Jacutin-Porte S, Taber MT, Gulwadi AG, Korpinen CD, Burris KD, Molski TF, Ryan E, Xu C, Wong H, Zhu J, Krishnananthan S, Gao Q, Verdoorn T, Johnson G (2002). „(+)-Dinapsoline: an efficient synthesis and pharmacological profile of a novel dopamine agonist”. Journal of Medicinal Chemistry. 45 (17): 3660—8. PMID 12166939. doi:10.1021/jm0101545.
^ Sit SY, Xie K, Jacutin-Porte S, Boy KM, Seanz J, Taber MT, Gulwadi AG, Korpinen CD, Burris KD, Molski TF, Ryan E, Xu C, Verdoorn T, Johnson G, Nichols DE, Mailman RB (2004). „Synthesis and SAR exploration of dinapsoline analogues”. Bioorg. Med. Chem. 12 (4): 715—34. PMID 14759732. doi:10.1016/j.bmc.2003.11.015.
^ Gleason SD, Witkin JM (2006). „Effects of dopamine D1 receptor agonists in rats trained to discriminate dihydrexidine”. Psychopharmacology (Berl.). 186 (1): 25—31. PMID 16575553. doi:10.1007/s00213-006-0342-2.

Spoljašnje veze

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[pmid11160615-1] Gulwadi AG, Korpinen CD, Mailman RB, Nichols DE, Sit SY, Taber MT (2001). „Dinapsoline: characterization of a D1 dopamine receptor agonist in a rat model of Parkinson's disease”. The Journal of Pharmacology and Experimental Therapeutics. 296 (2): 338—44. PMID 11160615.

[pmid8558526-2] Ghosh D, Snyder SE, Watts VJ, Mailman RB, Nichols DE (1996). „9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore”. Journal of Medicinal Chemistry. 39 (2): 549—55. PMID 8558526. doi:10.1021/jm950707.

[pmid12166939-3] Sit SY, Xie K, Jacutin-Porte S, Taber MT, Gulwadi AG, Korpinen CD, Burris KD, Molski TF, Ryan E, Xu C, Wong H, Zhu J, Krishnananthan S, Gao Q, Verdoorn T, Johnson G (2002). „(+)-Dinapsoline: an efficient synthesis and pharmacological profile of a novel dopamine agonist”. Journal of Medicinal Chemistry. 45 (17): 3660—8. PMID 12166939. doi:10.1021/jm0101545.

[pmid14759732-4] Sit SY, Xie K, Jacutin-Porte S, Boy KM, Seanz J, Taber MT, Gulwadi AG, Korpinen CD, Burris KD, Molski TF, Ryan E, Xu C, Verdoorn T, Johnson G, Nichols DE, Mailman RB (2004). „Synthesis and SAR exploration of dinapsoline analogues”. Bioorg. Med. Chem. 12 (4): 715—34. PMID 14759732. doi:10.1016/j.bmc.2003.11.015.

[pmid16575553-5] Gleason SD, Witkin JM (2006). „Effects of dopamine D1 receptor agonists in rats trained to discriminate dihydrexidine”. Psychopharmacology (Berl.). 186 (1): 25—31. PMID 16575553. doi:10.1007/s00213-006-0342-2.

[1]

[2]

[3]

[4]

[5]